Loading
CUSP06 is an experimental antibody-drug conjugate from OnCusp Therapeutics, in phase 1 trials for platinum-resistant ovarian cancer, renal cell carcinoma and CDH6-positive solid tumours.
CUSP06 (AMT-707) is an antibody-drug conjugate from OnCusp Therapeutics, with Multitude Therapeutics as licensor (retains Greater China rights). A cadherin-6 (CDH6)-directed antibody-drug conjugate: a CDH6-binding antibody joined by a protease-cleavable linker to an exatecan payload, a topoisomerase-1 inhibitor, with a drug-to-antibody ratio of eight. Its furthest stage is phase 1, for platinum-resistant ovarian cancer, renal cell carcinoma and CDH6-positive solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1b portion of a phase 1 study; NCT06234423 recruiting on the registry (checked 3 Nov 2026). FDA Fast Track in platinum-resistant ovarian cancer per the October 2026 release. Whether it works in people has not been established unless a trial below reports it.
A cadherin-6 (CDH6)-directed antibody-drug conjugate: a CDH6-binding antibody joined by a protease-cleavable linker to an exatecan payload, a topoisomerase-1 inhibitor, with a drug-to-antibody ratio of eight. Connects to CDH6.
1.CUSP06's antibody arm binds CDH6 on the surface of the cancer cell.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"CUSP06" OR ABSTRACT:"CUSP06" OR TITLE:"AMT-707" OR ABSTRACT:"AMT-707") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CUSP06, not a curated reading list.
Shares Multitude Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Multitude Therapeutics and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Platinum-resistant ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/